A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).
Aurelius Gabriel Omlin
Consultant or Advisory Role - AstraZeneca
Robert J. Jones
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Ruud van der Noll
No relevant relationships to disclose
Janet Graham
No relevant relationships to disclose
Michael Ong
No relevant relationships to disclose
Richard D. Finkelman
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Jan HM Schellens
No relevant relationships to disclose
Andrea Zivi
No relevant relationships to disclose
Mateus Crespo
No relevant relationships to disclose
Glen Clack
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Joshi J. Alumkal
No relevant relationships to disclose
Angela Dymond
Employment or Leadership Position - AstraZeneca
Andrew Dickinson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Malcolm Ranson
No relevant relationships to disclose
Michael D Malone
Employment or Leadership Position - AstraZeneca
Johann Sebastian De Bono
Employment or Leadership Position - Institute of Cancer Research, ICR
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Tony Elliott
Consultant or Advisory Role - AstraZeneca